MOVISCOM is totally focused on R&D both for the study of new formulations and for the conduction of clinical trials on the new products, in cooperation with local and international universities centers.

Currently the main interest of MOVISCOM is the treatment of patients suffering from metabolic diseases, in particular Hyperphenylalaninemia (HPA) and Phenylketonuria (PKU).

Subjects affected by these diseases, have an impaired conversion of phenylalanine to tyrosine resulting in an increased concentration of phenylalanine and its derivatives in blood and urine. The accumulation of phenylalanine in blood can cause irreversible damages to the nervous system (Severe Mental Retardation) and growth retardation. If the phenylalanine is not constantly kept within the safety range it can also lead to premature death. The diagnosis is performed through neonatal screening tests during the first days of life.

These metabolic syndromes can be kept under control, through a diet management based on the use of L-aminoacid supplements,phenylalanine-free. However these specific products should not be used as the only source of nutrients since the phenylalanine is essential for the normal human metabolic functioning. The diet plan tailored by the specialist for its patients should supply a minimum daily amount of phenylalanine.